Investment Portfolio

We have the expertise. We have the track record. We put Ontario First. FACIT actively manages its diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development. Our active portfolio consists of both early-stage assets and more than 35 companies advancing oncology therapeutics, medical technologies, diagnostics and informatics/AI. Our portfolio has raised more than $1.6B from global investors in follow-on financing.

Investment Philosophy

FACIT strategically invests in oncology breakthroughs and companies arising from Ontario’s outstanding innovation ecosystem. By fostering a culture of entrepreneurship and commitment to the value of commercialization, we support inventors and researchers in capitalizing on their cancer related innovations.

Why invest with FACIT

Our partners gain access to outstanding science and oncology innovations in a variety of areas such as new technology, therapeutics, imaging and diagnostics. Through our expertise in identifying and commercializing the most promising assets, we help investors reduce the risk of their early-stage involvement.

SEARCH FILTERS:

Innovation Type
Cancer Type
Current Funding Stage
FACIT Fund


Sort by:

Virano Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Developing the next generation of enhanced gene therapies using Vector Potentiators (VEPO)

DTPx Therapeutics (UHN)

Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes, Prospects
DTPx Therapeutics (University Health Network) is aiming to prevent relapse in colorectal cancer patients using a novel cell-based immunotherapy targeting a newly identified group of hibernating and drug tolerant cancer cells.

Point Surgical Inc.

Innovation Type:
Diagnostics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes, Prospects
Instant and accurate intra-surgical identification of cancer types or subtypes in under 10 secons through combining laser vaporization and mass spectrometry

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Enhanced Target Screening for WD Repeat Platform

OICR

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
OICR Target Prioritization Platform

Hyivy Health

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Proof Of Concept
Fund:
Compass Rose, Prospects
Remote patient monitoring, pelvic rehab system for gynecological and colorectal cancer patients and their clinicians

HDAX Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof Of Concept
Fund:
Prospects
A blood-brain barrier permeable HDAC6 selective inhibitors for CNS cancers based on proprietary technology that unlocks novel binding mechanism for improved next-gen targeting.

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Innovative quantum computing based technology (QuAccel) to screen protein-ligand interactions with higher speed and accuracy for drug discovery projects

Air Microfluidic Systems Inc.

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes, Prospects
Air microfluidics-enabled active compression sleeve for treating breast cancer-related lymphedema

Tenomix

Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose, Prospects
The first-ever automated, bench-top robotic scanning device for the detection of lymph nodes in surgically removed colorectal cancer tissue, making this step less labour intensive, less costly, and more reliable resulting in better patient care.

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Prostate
Funding Stage:
Proof of Concept
Fund:
Prospects
At-home prostate cancer screening kit

doctalk

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
A virtual space for physicians to collaborate with each other and organizations

Bridge7 Oncology

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes, Prospects
Scaling clinical expertise with AI to automate and improve the delivery of cancer care

Replica Analytics (Aetion)

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Prospects
Modeling software to generate synthetic data that protects the individual privacy of data subjects and maintains the statistical properties of real data. This enables easy, fast and effective access to high utility data that is made portable through data simulators

Multimagnetics Inc.

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Hand-held photoacoustic device to detect tumour margins and residual disease in the surgical cavity during breast-conserving surgery

University of Toronto

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Development of small-molecule inhibitors of mitochondrial RNA polymerase (POLRMT) as an anticancer strategy

Radiant Biotherapeutics

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
An antibody platform company developing multi-valent, multi-specific therapeutics, called Multabodies, to deliver transformative therapies for patients.

cTRL Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose
Harnessing the power of cTRLs (circulating tumor-reactive lymphocytes) in the blood to unlock the next generation of solid tumor cancer therapies.

Xpan Inc

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Falcons’ Fortunes, Prospects
Xpan’s Universal Trocar System is a minimally invasive surgical innovation – a first of its kind, radially expanding trocar that can be tailored by surgeons during laparoscopic procedures to accommodate various sized instruments.

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
WD Repeat Platform

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy

University of Toronto (Perturba)

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time

Polumiros

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Falcons’ Fortunes, Prospects
ReFilx, a polymeric soft tissue filler for the permanent restoration of breast tissue defects following lumpectomy

Talon Pharmaceuticals

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Prospects
Developing a novel series of small molecule drugs to induce apoptosis and impede cancer cell proliferation

Notch Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Notch Therapeutics has developed best-in-class, off-the-shelf, iPSC-derived synthetic T cells of unprecedented scale and functionality to further the advancement of cellular immunotherapies for patients and their families.

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
ADC-Linker Platform

QurCan Therapeutics (formerly Nanology Labs)

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
QurCan Therapeutics is fostering scientific creativity and pioneering a proprietary nanoparticle drug delivery technology called TERP to accelerate ​advanced nanomedicine-based therapeutics.

16-Bit

Innovation Type:
Informatics & AI
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Prospects
Automatic analysis of screening mammograms for breast cancer

DNAstack

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
Development of a cloud platform for genomics data management, analysis and sharing

Dalriada Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Seed
Fund:
Prospects
Developing a DT-1 class of small molecules, for the treatment of leukemia, with selective cancer cell-killing activity and reduced toxicity due to a unique cloaking mechanism.

KA Imaging

Innovation Type:
Medical Technologies
Cancer Type:
Other
Funding Stage:
Seed
Fund:
Compass Rose, Prospects
World’s first and only portable dual-energy detector, enabling bone and soft tissue differentiation in a single, highly sensitive x-ray exposure.

Radialis Medical

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Seed
Fund:
Prospects
Radialis Medical is developing an advanced Positron Emission Mammography (PEM) system for highly sensitive molecular (or functional) imaging of small pre-invasive cancerous breast lesions independent of breast tissue density.

Ottawa Hospital Research Institute

Innovation Type:
Therapeutics
Cancer Type:
pancreas
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer

OICR

Innovation Type:
Diagnostics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Molecular Profiling for Anthracycline Sensitivity in Patients receiving Chemo for Breast Cancer

Propellon Therapeutics Inc. (Triphase Accelerator)

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
Developing potent and selective small molecule WDR5 inhibitors for the treatment of leukemias and solid tumours

Pattern Pharma (formerly Realist Pharma)

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Prospects
Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.

Queen’s University

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Prospects
Development of Novel CYP26 Inhibitors for the treatment of AML

Fusion Pharmaceuticals Inc

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Next-generation radiopharmaceuticals for precision medicine (antibody conjugate for lung cancer), providing a safer approach to targeted radiotherapy by helping the drug clear from normal, healthy tissues and reducing toxicity

Novera Therapeutics Inc.

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Seed
Fund:
Compass Rose
Development of BCL6 inhibitors for the treatment of hematological cancers

FocusOnCare

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
ChemoTracker App Development

Capnostics

Innovation Type:
Medical Technologies
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Prospects
CellMate product for esophageal cell sampling. Acquired by PAVmed.

Sunnybrook Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
External Clinical Validation Study of a Quantitative Ultrasound Spectral Analysis Platform For Monitoring Tumor Response In Women Receiving Neoadjuvent Chemotherapy for Locally Advanced Breast Cancer

OICR

Innovation Type:
Diagnostics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Ring Study to Evaluate the PRedicTive brEast Cancer Test (PRoTECT)

Sunnybrook Research Institute

Innovation Type:
Therapeutics
Cancer Type:
Breast
Funding Stage:
Proof of Concept
Fund:
Prospects
Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and GSK AS15 adjuvant

Ziliomics

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose, Prospects
Development of heliotrope bioinformatics software platform

Sunnybrook Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Falcons’ Fortunes
Ultra-Low Dose Microbubbles for Cancer

OICR

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Prospects
Fully synthetic, self-adjuvanting vaccines incorporating tumor-associated antigenic epitopes for cancer immunotherapy

Turnstone Biologics Inc

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Developing next-generation tumor infiltrating lymphocytes (TIL) therapies by selecting the most potent and tumor-reactive T cells for potential treatment across multiple solid tumors

Fluorinov Pharma (Trillium)

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Exit
Fund:
Compass Rose
Breakthrough medicinal chemistry technology enabling fluorine atoms linked to drug candidates to improve therapeutic potency, stability and safety. The lead candidate, FV162, is an oral proteasome inhibitor for the treatment of blood cancers.

OICR (Cellax)

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Cellax is a self-assembling nanoparticle drug-polymer conjugate that selectively targets tumour cells for enhanced cancer treatment with fewer side effects.

XLV Diagnostics

Innovation Type:
Medical Technologies
Cancer Type:
Breast
Funding Stage:
Series A,B,C
Fund:
Compass Rose
X-ray light valve (XLV) for low-cost digital mammography

Privacy Analytics (IQVIA)

Innovation Type:
Informatics & AI
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Software unlocking the vast potential of medical data without compromising individual privacy or causing unacceptable distortion of the data

Arrayus Technologies (formerly Harmonic Medical)

Innovation Type:
Medical Technologies
Cancer Type:
Liver
Funding Stage:
Series A,B,C
Fund:
Compass Rose
A system using ultrasound to both detect and treat tumours in bone and liver for the relief of pain without surgery and without expensive imaging equipment

McMaster University

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of Radiolabeled Insulin Probe

Triphase Accelerator Corporation

Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Series A,B,C
Fund:
Compass Rose
Triphase Accelerator is dedicated to advancing novel compounds from pre-IND through Phase 2 clinical proof-of-concept studies using a unique, science-based model that is faster and more cost-effective than traditional pharmaceutical industry approaches.

Kapplex

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
A Digital Microfluidics Platform for High-Throughput Apoptosis Screening

Xagenic

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Point-of-care platform for decentralized, rapid molecular diagnostic testing including GenEplex platform for clinically accepted leukemia biomarkers.

DLVR Therapeutics

Innovation Type:
Therapeutics
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel nanoparticle delivery technology

University of Toronto (Receptor-OncoTek)

Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Preclinical development of PoLi-PTX, Intraperitoneal Ovarian Cancer Therapy

DVS Sciences (Fluidigm/Standard BioTools)

Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Flow cytometer-mass spectrometer for multi-parametric cell and bead analysis

UHN (TorCell Therapeutics)

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel T-cell Immunotherapy (autologous cellular therapy)

UHN

Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of novel chemical proteosome inhibitors

Sunnybrook Research Institute

Innovation Type:
Diagnostics
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Glypican-3: a novel marker for the early diagnosis of hepatocellular carcinoma

UHN

Innovation Type:
Medical Technologies
Cancer Type:
Liver
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Novel Radio Frequency Ablation Technology for Treatment of Solid Tumours

ArcticDx

Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Compass Rose
Development of a colon cancer risk prediction diagnostic tool

Robarts Research Institute

Innovation Type:
Medical Technologies
Cancer Type:
Prostate
Funding Stage:
Proof of Concept
Fund:
Compass Rose
3D ultrasound-guided intraoperative and dynamic minimally invasive trans-perineal prostate therapy and biopsy platform

Profound Medical

Innovation Type:
Medical Technologies
Cancer Type:
Prostate
Funding Stage:
Exit
Fund:
Compass Rose
MRI-guided transurethral ultrasound therapy for localized prostate cancer


FACIT has been nationally recognized by industry peers with a Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA). The award acknowledges FACIT’s strategic commercialization investments that have positioned our portfolio companies to deliver meaningful impacts on Ontario’s life sciences industry. FACIT is the first and only Ontario life science commercialization organization to achieve this recognition.


    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.